Department of Defense HIV/AIDS Prevention Program
Open
Defense Health Agency Contracting Activity - DHACA is offering grants to any type of organization. It expects to make about 10 awards. Applications close on September 18, 2027.
From the official notice on Grants.gov, last changed April 2, 2026. Checked October 31, 2026.
- Award ceilingnot stated
- Award floornot stated
- Expected awards10
- Total fundingnot stated
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | September 19, 2022 |
|---|---|
| Deadline | September 18, 2027 |
| Archived by Grants.gov | October 18, 2027 |
Add the deadline to your calendar
Who can apply
This opportunity is open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
ATTENTION: This announcement will be revised regularly to incorporate country specific narratives (Attachment 1 of the announcement) with information vital to the content of application. Potential applicants interested in applying to this announcement should click 'Subscribe' to be notified of future revisions. DoD HIV/AID Prevention Program's (DHAPP) objective, through the PEPFAR program, is to save lives, prevent HIV infections, and accelerate progress toward achieving HIV/AIDS epidemic control and to support the development of interventions and programs in military health systems that address these issues. DHAPP works with militaries of foreign countries to devise plans based on the following process: Meet with key partners in country to determine provisional major program areas and other technical assistance needs. Adapt DHAPP support to a country’s need for prevention, care and/or treatment of its HIV/AIDS situation based on an assessment of the country’s epidemic, and more specifically, in that country’s military. Strengthen the military capacity for ownership and behavioral changes over the long term. Consider program design by leveraging assets with other country partners who have/had successful prevention, care, and/or treatment efforts. Focus on prevention, care and/or treatment impact aligned with national implementation plans. Implement and monitor programs to ensure accountability and sustainability. Countries and their militaries need strong evidenced based HIV programs with measurable courses of action that demonstrate the following specific attributes. Priorities for DHAPP include the following but are subject to change. Support and ownership from the military sector. Development of plans of action and support for military policies that further HIV epidemic control. Alignment with PEPFAR and national strategies and priorities. Testing and treatment expansion to meet 2020 goals of 90-90-90 and 2030 goals of 95-95-95 for people living with HIV.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to Christopher Meinberg, Grantor, ebony.s.simmons.civ@health.mil, 3016192657.
Questions people ask
Who can apply for Department of Defense HIV/AIDS Prevention Program?
Defense Health Agency Contracting Activity - DHACA accepts applications from any type of organization.
What is the deadline for Department of Defense HIV/AIDS Prevention Program?
Closes September 18, 2027 (322 days left). Confirm the date and time in the official notice on Grants.gov.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience